In NSCLC patients with EGFR-TKI resistance associated with MET amplification, combining EGFR-TKIs with a MET inhibitor has shown benefit in several trials.54,70,71 The present work demonstrates that, in addition to osimertinib, the MUC1-C inflammatory response confers resistance to MET TKIs and the combination of osimertinib+MET TKIs. Here, MET is linked to non-small cell lung carcinoma.